一种新型PSMA-PI3K小分子药物合物的设计,合成和生物评估

Shouguo Peng1,2,3, Haixia Li4, Weilu Cui4

  • 1State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100050 China jiming@imm.ac.cn xuheng@imm.ac.cn.

RSC medicinal chemistry
|September 9, 2024
PubMed
概括

一种新的小分子药物合物向前列腺特异性膜抗原 (PSMA) 和PI3K,显示选择性癌细胞生长抑制. 这种PSMA-PI3K结合物在针对癌症治疗的临床前模型中显示出强大的疗效和耐受性.